- Rare and Orphan Disease Focused
- Experienced Management Team
- Rare Pediatric Designation opportunity for lead products
- Targeting Approval for lead asset in 2024.
- Internal commercial infrastructure planned for US and EU markets. Marketing partnerships established spanning 60 countries
- Strong KOL support
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical stage specialty pharmaceutical company focused on the development and commercialization of therapeutic drug products that treat rare and orphan diseases. Our mission is very simple; to bring hope where there is currently none. We are totally committed to addressing critical, unmet medical needs for patients, their families, communities and care teams.
Quoin’s innovative pipeline comprises four products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, Scleroderma and others. The company plans to establish a sales infrastructure to commercialize its products in both US and Europe and has entered into eight separate strategic licensing partnerships spanning 60 countries including Canada, Australia, New Zealand, the Middle East, China, Hong Kong, Taiwan, Central and Eastern Europe, the Baltic States and several countries in Latin America.
We are dedicated to finding unique solutions for rare and orphan indications and will continue to expand our pipeline of products to address the unmet needs of underserved and neglected patient populations.
First Patient Dosed in Open Label Netherton Syndrome Clinical Trial
Closing of $7.0 Million Public Offering
Second Netherton Syndrome clinical study cleared by FDA to initiate testing.
First patient dosed in clinical trial in Netherton Syndrome.
Second clinical study announced, evaluating QRX003 in Netherton Syndrome patients receiving off-label systemic therapy.
Three clinical sites open, patient website established from Netherton Syndrome study
$16.8 million oversubscribed and upsized public offering
Scientific Advice received from EMA
Commercialization agreement signed for Canadian market
First site opened for Netherton Syndrome clinical study
Distribution agreement covering Greater China
Second exclusive research agreement with QUT for scleroderma treatment
FDA clearance of IND for QRX003 for Netherton Syndrome
Submits Investigational New Drug application to FDA and Scientific Advice Briefing document to EMA
Marketing partnerships for distribution of QRX003 in Israel and to 21 European countries
Exclusive distribution in key Latin America markets
Exclusive distribution agreements signed, covering the Middle East, North Africa and Australasia
Funding of pre-clinical program to investigate a bi-functional protein at Queensland University of Technology
Quoin Pharmaceuticals begins trading on Nasdaq